AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19804954 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher glycemic index diet
Number of subjects: 12
Study 19804954 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower glycemic index diet
Number of subjects: 12
Study 19804954 — intervention group
Group type: COMPARATOR
Intervention: Controlled feeding days
Number of subjects: 12
Study 17397428 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 112
Study 17397428 — intervention group
Group type: COMPARATOR
Intervention: Health education
Number of subjects: 112
Study 15642302 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-spherical polyvinyl alcohol (PVA) 355-500 microm
Number of subjects: 17
Study 15642302 — intervention group
Group type: COMPARATOR
Intervention: Trisacryl gelatin microspheres (MS) 700-900 microm
Number of subjects: 17
Study 12271345 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaflur
Number of subjects: 0
Study 12271345 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleaflur
Number of subjects: 0
Study 12271345 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride
Number of subjects: 0
Study 12271345 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental fluoride containing hydrolyzed casein
Number of subjects: 0
Study 12271345 — intervention group
Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 0
Study 10097858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial 5-FU
Number of subjects: 0
Study 10097858 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial FUdR
Number of subjects: 0
Study 10097858 — intervention group
Group type: COMPARATOR
Intervention: Systemic treatment
Number of subjects: 0
Study 7736673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 1,200 mg/d for 4 months
Number of subjects: 86
Study 7736673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 2202990 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency recruitment plan
Number of subjects: 0
Study 7276229 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-30 mg/day molindone
Number of subjects: 20
Study 7276229 — intervention group
Group type: COMPARATOR
Intervention: 20-30 mg tranylcypromine
Number of subjects: 20
Study 7276229 — intervention group
Group type: EXPERIMENTAL
Intervention: molindone
Number of subjects: 20
Study 7276229 — intervention group
Group type: COMPARATOR
Intervention: tranylcypromine
Number of subjects: 20
Study 30940890 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded HbA1c genetic risk score (GRS) with 17 HbA1c-related common variants
Number of subjects: 11935
Study 30940890 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative HbA1c genetic risk score (GRS) by excluding 11 variants
Number of subjects: 11935
Study 28646841 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 28
Study 28646841 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral anti‐spastic medications and stretching exercises)
Number of subjects: 28
Study 24249542 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pelvic floor muscle therapy (PFMT) with biofeedback once a week for 4 weeks preoperatively
Number of subjects: 122
Study 24249542 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 122
Study 23897970 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg orally twice per day for 14 days
Number of subjects: 84
Study 23897970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 21724008 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (20%)
Number of subjects: 29
Study 21724008 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic isoncotic saline (HIS)
Number of subjects: 29
Study 19682403 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamins supplementation for 3 months
Number of subjects: 37
Study 19682403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 19682403 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinaemic subjects
Number of subjects: 37
Study 19682403 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37
Study 17912233 — intervention group
Group type: EXPERIMENTAL
Intervention: Uretero-vescical anastomosis according to Lich-Gregoir (group A)
Number of subjects: 36
Study 17912233 — intervention group
Group type: COMPARATOR
Intervention: Uretero-vescical anastomosis according to Knechtle (group B)
Number of subjects: 36
Study 15090796 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell count‐driven structured treatment interruption (STI) strategy
Number of subjects: 69
Study 15090796 — intervention group
Group type: COMPARATOR
Intervention: Continuous highly active antiretroviral therapy
Number of subjects: 69
Study 11253966 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (20 mg/m2 cisplatin on days 1-5, 100 mg/m2 etoposide on days 1-5, 30 kU bleomycin on days 1, 8, and 15, repeated every 21 days)
Number of subjects: 166
Study 11253966 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (100 mg/m2 cisplatin on day 1, 120 mg/m2 etoposide on days 1-3, 30 kU bleomycin on day 1, repeated every 21 days)
Number of subjects: 166
Study 9633761 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus paracetamol
Number of subjects: 71
Study 9633761 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol only
Number of subjects: 71
Study 9633761 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study 7706572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide inhaled at 32 vpm
Number of subjects: 5
Study 7706572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide inhaled at 64 vpm
Number of subjects: 5
Study 7706572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide inhaled at 128 vpm
Number of subjects: 5
Study 7706572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide inhaled at 512 vpm
Number of subjects: 5
Study 3664948 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: early instillation of adriamycin with oral administration of 5‐fluorouracil (200 mg/day)
Number of subjects: 199
Study 3664948 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: early instillation of adriamycin (30 mg/30 ml)
Number of subjects: 199
Study 3664948 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: delayed instillation of adriamycin (30 mg/30 ml)
Number of subjects: 199
Study 3664948 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D: delayed instillation of adriamycin with oral administration of 5‐fluorouracil (200 mg/day)
Number of subjects: 199
Study 3664948 — intervention group
Group type: EXPERIMENTAL
Intervention: Early instillation groups
Number of subjects: 199
Study 3664948 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed instillation groups
Number of subjects: 199
Study 29898707 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA 10 mg/kg IV 10 min prior to tourniquet deflation
Number of subjects: 64
Study 29898707 — intervention group
Group type: COMPARATOR
Intervention: Topical TXA 1.0 g diluted in 50 ml normal saline injected into surgical site prior to tourniquet deflation
Number of subjects: 64
Study 28065180 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised dietary advice
Number of subjects: 0
Study 24999481 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS in one step (Group I)
Number of subjects: 0
Study 24999481 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS with retest (Group II)
Number of subjects: 0
Study 24999481 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of hearing loss
Number of subjects: 0
Study 24360041 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus CT-guided percutaneous RFA in special location group
Number of subjects: 36
Study 24360041 — intervention group
Group type: COMPARATOR
Intervention: TACE plus CT-guided percutaneous RFA in non-special location group
Number of subjects: 36
Study 24360041 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications in special location group
Number of subjects: 36
Study 24360041 — intervention group
Group type: COMPARATOR
Intervention: Complications in non-special location group
Number of subjects: 36
Study 20572834 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implant treatment with two implants and a new denture with magnet-, ball-socket, and bar-clip attachments
Number of subjects: 18
Study 18438563 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonated drink
Number of subjects: 3
Study 18438563 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 3
Study 18438563 — intervention group
Group type: COMPARATOR
Intervention: Tap water (control)
Number of subjects: 3
Study 17030762 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation
Number of subjects: 60
Study 17030762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12746776 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin
Number of subjects: 30
Study 12746776 — intervention group
Group type: COMPARATOR
Intervention: No treatment for HCV infection
Number of subjects: 30
Study 11319683 — intervention group
Group type: EXPERIMENTAL
Intervention: ART plus IL‐2 (12 million IU by continuous intravenous infusion, followed by 7.5 MIU twice a day, sc, every 8 weeks)
Number of subjects: 61
Study 11319683 — intervention group
Group type: EXPERIMENTAL
Intervention: ART plus IL‐2 (7.5 MIU twice a day, sc, every 8 weeks)
Number of subjects: 61
Study 11319683 — intervention group
Group type: EXPERIMENTAL
Intervention: ART plus IL‐2 (3 MIU twice a day, sc, every 4 weeks)
Number of subjects: 61
Study 11319683 — intervention group
Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 61
Study 9129766 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) during CVVHDF
Number of subjects: 6
Study 9129766 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVHDF
Number of subjects: 6
Study 8184997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment (12 weeks)
Number of subjects: 21
Study 8184997 — intervention group
Group type: COMPARATOR
Intervention: Supportive drug maintenance and slow, flexible drug taper (alprazolam-only group)
Number of subjects: 21
Study 8184997 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (cognitive behavioral treatment + supportive drug maintenance)
Number of subjects: 21
Study 8184997 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam-only group
Number of subjects: 21
Study 3332681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglioside administration (40 mg intramuscular daily)
Number of subjects: 30
Study 31153990 — intervention group
Group type: EXPERIMENTAL
Intervention: Etizolam 0.25 mg
Number of subjects: 16
Study 31153990 — intervention group
Group type: EXPERIMENTAL
Intervention: Etizolam 1.00 mg
Number of subjects: 16
Study 31153990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 28501140 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib 300 mg twice daily
Number of subjects: 207
Study 28501140 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 207
Study 25883952 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity laser therapy (10 sessions)
Number of subjects: 65
Study 25883952 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (10 sessions)
Number of subjects: 65
Study 25883952 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy and isometric lumbar exercises (10 days)
Number of subjects: 65
Study 24520889 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary bereavement care intervention by trained family physicians for widows (43 widows, 7 sessions from 4th to 13th month after loss)
Number of subjects: 87
Study 24520889 — intervention group
Group type: COMPARATOR
Intervention: Ordinary appointments by untrained family physicians for widows (44 widows, 7 sessions with the same schedule)
Number of subjects: 87
Study 21624837 — intervention group
Group type: COMPARATOR
Intervention: Hepatic artery embolization (HAE)
Number of subjects: 50
Study 21624837 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal vein (PV) embolization
Number of subjects: 50
Study 21624837 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PV embolization to HAE
Number of subjects: 50
Study 18049092 — intervention group
Group type: EXPERIMENTAL
Intervention: N-butylscopolamine (20 mg intravenously)
Number of subjects: 72
Study 16605293 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pimecrolimus cream
Number of subjects: 0
Study 16605293 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 12960187 — intervention group
Group type: COMPARATOR
Intervention: (18)F-FDG
Number of subjects: 26
Study 12960187 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FLT
Number of subjects: 26
Study 10834774 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of 0.1% ropivacaine with fentanyl 2 microg/mL and epinephrine 1:400,000 (REF)
Number of subjects: 34
Study 10834774 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline
Number of subjects: 34
Study 9663837 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron (4 mg)
Number of subjects: 12
Study 9663837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8459057 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000-calorie meal
Number of subjects: 20
Study 31190058 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28395396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender-sandalwood aromatherapy tab
Number of subjects: 87
Study 28395396 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange-peppermint aromatherapy tab
Number of subjects: 87
Study 28395396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 24859616 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 0
Study 24859616 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (placebo)
Number of subjects: 0
Study 23408562 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet + PCD
Number of subjects: 50
Study 23408562 — intervention group
Group type: COMPARATOR
Intervention: Internet- alone
Number of subjects: 50
Study 22696626 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (frequency=28 Hz; amplitude 0.97 mm)
Number of subjects: 4
Study 22696626 — intervention group
Group type: COMPARATOR
Intervention: Control condition (machine turned off)
Number of subjects: 4
Study 18398548 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15816569 — intervention group
Group type: EXPERIMENTAL
Intervention: High bolus dose of cisatracurium (0.4 mg kg(‐1)) in Group 1
Number of subjects: 20
Study 15816569 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of cisatracurium (0.1 mg kg(‐1) at induction followed by continuous infusion) in Group 2
Number of subjects: 20
Study 15816569 — intervention group
Group type: EXPERIMENTAL
Intervention: Total amount of cisatracurium used
Number of subjects: 20
Study 12598068 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 30
Study 12598068 — intervention group
Group type: COMPARATOR
Intervention: Control (no spironolactone)
Number of subjects: 30
Study 10547208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with insulin and sulphonylureas (glibenclamide 10.5 mg daily)
Number of subjects: 15
Study 8638193 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine derivatives of sulfasalazine
Number of subjects: 0
Study 8638193 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer steroid preparations (investigational)
Number of subjects: 0
Study 8638193 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive agents (6-mercaptopurine, azathioprine, methotrexate)
Number of subjects: 0
Study 8638193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 0
Study 8638193 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids and sulfasalazine (traditional therapy)
Number of subjects: 0
Study 1808488 — intervention group
Group type: EXPERIMENTAL
Intervention: Kybernin
Number of subjects: 32
Study 1808488 — intervention group
Group type: COMPARATOR
Intervention: Control (no Kybernin)
Number of subjects: 32
Study 6619270 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine treatment (3-5 weeks)
Number of subjects: 7
Study 6619270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 6619270 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine treatment
Number of subjects: 7
Study 31021875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative vertebral anesthesia (group B)
Number of subjects: 64
Study 31021875 — intervention group
Group type: COMPARATOR
Intervention: Traditional local anesthesia (group A)
Number of subjects: 64
Study 29167041 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral stress management program (IB-CBSM)
Number of subjects: 93
Study 29167041 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) based on distraction
Number of subjects: 93
Study 29167041 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IB-CBSM and CG
Number of subjects: 93
Study 27560995 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily motivation and self-efficacy assessments via ecological momentary assessment (EMA)
Number of subjects: 96
Study 27560995 — intervention group
Group type: COMPARATOR
Intervention: Control for between-person associations and prior drinking
Number of subjects: 96
Study 24293175 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopic measurement of right-to-left interlead distance (2DAP)
Number of subjects: 49
Study 24293175 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopic measurement of right-to-left interlead distance (2DLL)
Number of subjects: 49
Study 24293175 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to CRT
Number of subjects: 49
Study 22389967 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociceptive trigeminal inhibitory tension suppression system (NTI-tss)
Number of subjects: 10
Study 22389967 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal stabilization splint (OS)
Number of subjects: 10
Study 22389967 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 10
Study 22389967 — intervention group
Group type: COMPARATOR
Intervention: Micro-arousal index
Number of subjects: 10
Study 19786664 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP treatment (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 119
Study 19786664 — intervention group
Group type: EXPERIMENTAL
Intervention: BCL6 breakpoint
Number of subjects: 119
Study 19786664 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical markers (CD10, BCL6, MUM1/IRF4, LMO2, FOXP1)
Number of subjects: 119
Study 17715638 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100‐200 mg/d and furosemide 20‐40 mg/d
Number of subjects: 0
Study 17715638 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial therapeutic paracentesis, transjugular intrahepatic stent‐shunt (TIPS), peritoneovenous shunt, liver transplantation
Number of subjects: 0
Study 15118188 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-mineral supplementation
Number of subjects: 2
Study 15118188 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study 11780794 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task condition (tapping task)
Number of subjects: 39
Study 11780794 — intervention group
Group type: COMPARATOR
Intervention: Standard conditions (control group)
Number of subjects: 39
Study 9715735 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal breathing
Number of subjects: 10
Study 9715735 — intervention group
Group type: COMPARATOR
Intervention: Mouth breathing
Number of subjects: 10
Study 8152445 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (mean dose 212 +/- 68 mg per day)
Number of subjects: 70
Study 8152445 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 70
Study 3291041 — intervention group
Group type: EXPERIMENTAL
Intervention: Terodiline (25 mg daily)
Number of subjects: 42
Study 3291041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 30885799 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Duration Work Roster (EDWR) with shifts ≥24 h
Number of subjects: 6577
Study 30885799 — intervention group
Group type: COMPARATOR
Intervention: Rapidly Cycling Work Roster (RCWR) with shifts limited to a maximum of 16 h
Number of subjects: 6577
Study 28944752 — intervention group
Group type: COMPARATOR
Intervention: DVD intervention (self-guided breathing retraining with DVD and booklet)
Number of subjects: 655
Study 28944752 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face physiotherapy intervention (three sessions with a respiratory physiotherapist)
Number of subjects: 655
Study 28944752 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group (usual care)
Number of subjects: 655
Study 28944752 — intervention group
Group type: COMPARATOR
Intervention: DVD intervention
Number of subjects: 655
Study 28944752 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face physiotherapy intervention
Number of subjects: 655
Study 26158895 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper airway stimulation via hypoglossal nerve
Number of subjects: 0
Study 24112951 — intervention group
Group type: EXPERIMENTAL
Intervention: rVIIa-FP (140, 300, 500, 750, or 1000 μg kg(‐1))
Number of subjects: 40
Study 24112951 — intervention group
Group type: EXPERIMENTAL
Intervention: rVIIa-FP (1000 μg kg(‐1))
Number of subjects: 40
Study 24112951 — intervention group
Group type: EXPERIMENTAL
Intervention: rVIIa-FP
Number of subjects: 40
Study 21741829 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (X) 2500mg/m² on days 1-14, q3w
Number of subjects: 151
Study 21741829 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus capecitabine (XH) 6 (8)mg/kg, q3w
Number of subjects: 151
Study 21741829 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation/restart of anti-HER2 treatment (trastuzumab or lapatinib) after 2nd progression
Number of subjects: 151